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Abstract
Objectives. To characterize the in vitro binding and effector function properties of CD20-directed small
modular immunopharmaceutical (SMIP) 2LM20-4, and to compare its in vivo B-cell depletion activity with
the mutated 2LM20-4 P331S [no in vitro complement-dependent cytotoxicity (CDC)] and rituximab in
cynomolgus monkeys.
Methods. Direct binding is examined in flow cytometry, confocal microscopy, scatchard and lipid raft
assays. Effector function assays include CDC and Fc-mediated cellular toxicity. In the 6-month-long
in vivo B-cell depletion study, single i.v. dosages of 1 or 10mg/kg of anti-CD20 proteins were adminis-
tered to monkeys and B-cell counts were monitored in peripheral blood, bone marrow and lymph nodes.
Results. 2LM20-4 has lower saturation binding to human primary B cells and recruits fewer CD20 mol-
ecules into lipid rafts compared with rituximab; however, it induces higher in vitro CDC. In competitive
binding, 2LM20-4 only partially displaces rituximab, suggesting that it binds to a fraction of CD20 mol-
ecules within certain locations of the plasma membrane as compared with rituximab. In monkeys,
2LM20-4 had more sustained B-cell depletion activity than rituximab in peripheral blood and had signifi-
cantly more profound and sustained activity than 2LM20-4 P331S and rituximab in the lymph nodes.
Conclusions. SMIP 2LM20-4, which binds to a fraction of CD20 molecules as compared with rituximab,
has more potent in vitro CDC, and more potent and sustained B-cell depletion activity in cynomolgus
monkeys. Our work has considerable clinical relevance since it provides novel insights related to the
emerging B-cell depletion therapies in autoimmune diseases.
Key words: B-cell depletion, Autoimmune diseases, Anti-CD20 small modular immunopharmaceutical, In vitro
properties, In vivo properties.
Introduction
During the past decade, B cells have convincingly
emerged as critical players in the pathogenesis of auto-
immune disorders and novel therapeutic modalities
targeting B cells have been proven to be effective in auto-
immune diseases like RA and SLE [15]. To date, selective
B-cell depletion with the use of mAbs has shown much
promise in RA, and rituximab, a chimeric mAb that
binds to CD20 on B cells, is an Food and Drug
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failed to respond to anti-TNF therapies [6]. B-cell deple-
tion has also shown promising efficacy in SLE, multiple
sclerosis (MS) and autoimmune type I diabetes [713];
however, confirmation of this efficacy in controlled trials
has not yet been reported.
Anti-CD20 mAbs have been previously characterized as
either type I (rituximab-like), based on their ability to recruit
CD20 molecules into detergent-insoluble microdomains
and to activate complement-dependent cytotoxicity
(CDC), or type II (tositumomab/B1-like), based on their
ability to promote programmed cell death (PCD), but not
CDC [14, 15]. Potent CDC was thought to be primarily
related to the slowoff-rate of the anti-CD20 mAb; however,
it has been recently demonstrated that the CD20 epitope
recognized by the mAb is also another critical factor for the
induction of potent CDC [16]. Numerous in vitro studies
have demonstrated that rituximab bound to CD20
+ B
lymphoma cells redistributes CD20 molecules into lipid
rafts and mediates CDC, Fc-mediated cellular toxicity
and PCD in certain cell lines [17]. Also, pre-clinical in vivo
studies indicate that both CDC and Fc-mediated cellular
toxicity can contribute to mAb-induced tumour cell lysis
[1822]. However, evidence related to the relative clinical
importance of each mechanism, and whether they are
synergistic or antagonistic, is still conflicting [15]. The
mechanism by which rituximab causes B-cell depletion
in patients with RA and SLE is even more controversial
[15, 23], and, to date, it is still not known to what extent
CDC contributes to the success of anti-CD20 therapies in
RA [24]. The need to elucidate the mechanistic pathways
governing the success of B-cell depletion in the clinic insti-
gated the engineering of B-cell-depleting reagents with
modified effector function properties, and several such
drug candidates are currently being evaluated in the
clinic [5, 15, 25].
2LM20-4 is a humanized anti-CD20 small modular
immunopharmaceutical (SMIP) protein drug candidate
that is smaller than an antibody and is being developed
for the treatment of patients with autoimmune disorders.
In vitro binding and competition assays indicate that
2LM20-4 binds only to a fraction of CD20 molecules
within certain locations of the plasma membrane in
human primary B cells; however, it mediates more potent
CDC activity compared with rituximab. 2LM20-4 does not
induce in vitro PCD, but in the presence of effector cells, it
potentiates Fc-mediated cellular toxicity comparable with
rituximab. Notably, due to the decreased in vitro direct
binding of 2LM20-4, its inability to saturate CD20 on the
surface of primary B-cells, off-rate, competition and lipid
raft distribution assays, we would predict a lower in vivo
potency compared with rituximab. To elucidate how these
in vitro binding properties correlate with in vivo efficacy,
we compared 2LM20-4 with rituximab in a non-human
primate study. Also, considering the controversial role of
complement activation in B-cell depletion in autoimmune
diseases, we generated a variant 2LM20-4 with mutation
P331S in the Fc domain (2LM20-4 P331S), known to
reduce C1q binding and complement activation, and
used it as a comparator in the same study. We present
here that 2LM20-4 has significantly more potent and
sustained activity in the peripheral blood and the lymph
nodes compared with rituximab. Also, we show here that
mutation P331S significantly reduces B-cell depletion
activity in lymphoid tissues of cynomolgus monkeys.
Overall, our results suggest that 2LM20-4 has a unique
combination of in vitro binding and effector function prop-
erties thatcannot be characterized aseither type I ortype II
and can lead to profound in vivo B-cell depletion activity in
cynomolgus monkeys.
Materials and methods
Generation of 2LM20-4 and 2LM20-4 P331S SMIP
constructs
2LM20-4 was generated based on the mouse mAb 2H7,
which recognizes an extracellular loop of the human CD20
B-cell surface molecule [26, 27]. The variable regions of
2H7 were humanized by complementarity-determining
region (CDR) grafting and converted into a single-chain
variable fragment (scFv) variable lightvariable heavy
chain (VLVH) format using a flexible (Gly4Ser) 16-
amino-acid linker. 2LM20-4 SMIP protein was constructed
by fusing coding regions of humanized scFv with human
Immunoglobulin G1 heavy chain constant region 2 (CH2)
and heavy chain constant region 3 (CH3) domains
through the modified human IgG1 hinge sequence:
EPKSSDKTHTCPPCP. To generate 2LM20-4 P331S, pro-
line at position 331 was changed to serine in the constant
fragment (Fc) region by PCR mutagenesis. Coding regions
were sub-cloned into pSMED2 mammalian expression
vector and expressed in stable Chinese hamster ovary
(CHO) cell lines. Proteins were purified using a Protein
ASepharoseFFcolumn.Asizeexclusionchromatography
(SEC) column was used to remove aggregates. The purity
and molecular weight of proteins were confirmed by
SDSPAGE, analytical SEC and light-scatter analysis.
In vitro binding to primary B cells
Normal human primary B cells were isolated from buffy
coats by negative selection (RosetteSep human B cell
enrichment kit; StemCell Technologies, Vancouver, BC,
Canada) and were incubated with varying concentrations
of anti-CD20 proteins or a control IgG1 antibody for
30min on ice. A phycoerythrin-labelled anti-IgG antibody
(SouthernBiotech, Birmingham, AL, USA) was used for
detection of the anti-CD20 molecules, and 7-amino-
actinomycin D (7AAD; BD Biosciences, San Jose, CA,
USA) for exclusion of dead cells. Cells were analysed on
LSR II (Becton Dickinsosn, San Jose, CA, USA) and data
analysis was performed using FlowJo software 7.2.2
(TreeStar Inc., Ashland, OR, USA).
Confocal microscopy
Primary human B cells were pre-treated for 10min at room
temperature(RT)with250nMcontrolhumanIgG1andthen
treated for 10min at RT with biotinylated 2LM20-4, ritux-
imab or isotype control antibody. Cells were washed
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Carlsbad, CA, USA) for 30min at 4 C. Cells were washed,
spun onto microscope cover slips, fixed with Cytofix-
cytoperm (BD Biosciences, San Jose, CA, USA), washed
in 1:2perm/wash (BD Biosciences), and then stained with
TO-PRO 3 (Invitrogen). Cover slips were mounted using
Pro-Long (Invitrogen), and set overnight at RT. Slides
were read using a Nikon TE-300 microscope (Nikon
Instruments Inc., Melville, NY, USA) with Bio-Rad
Radiance 2000 confocal system.
Scatchard studies
Equilibrium dissociation constants (Kds) were determined
by radiolabelling 2LM20-4 and rituximab with
125Iodine
(1nmol/0.5mCi) using Pierce Iodotube tyrosine method
(Thermo Fisher Scientific, Rockford, IL, USA) and plating
them at 12 concentrations in triplicate (20pM to 40nM)±
100 unlabelled 2LM20-4 or rituximab in V-bottom
96-well tissue culture plates. Primary B cells were added
to the plates (37000200000 cells/well, depending on the
donor) and the plates were incubated overnight. Cells
were spun down, and cell pellets were solubilized with
100ml 1N NaOH for 10min and were counted in a
gamma counter (bound). GraphPad Prism software
(GraphPad Software, La Jolla, CA, USA) was used for
curve fitting. For competitive binding, a constant 5nM
125I-rituximab was combined with 12 concentrations of
unlabelled 2LM20-4 ranging from 100pM to 100nM in
triplicate.
Lipid rafts
To study the redistribution of CD20 molecules into low
density, detergent-insoluble membrane microdomains
(lipid rafts), we used the protocol previously described
for rituximab [28]. Primary B cells or Ramos B lymphoma
cells were incubated with iodinated 2LM20-4, rituximab or
isotype control (1mg/2 10
6cells) at 37 C for 060min.
Cells were spun down, and cell pellets were lysed with
ice-cold 0.5% Triton X-100 for 15min. Lysates were
spun down at 14000g for 15min at 4 C to separate in-
soluble material. Soluble and insoluble lysate fractions
were counted on a gamma counter followed by the deter-
mination of the distribution of radio labelled proteins in the
soluble (monomeric or weakly associated with lipid rafts)
vs insoluble (strongly associated with lipid rafts) fractions.
In vitro CDC assays
Primary human B cells were plated at 1 10
5cells/well in
media containing RPMI 1640, 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid and 10% normal human serum
complement (Quidel, Santa Clara, CA, USA). Varying con-
centrations of SMIP proteins, rituximab or control anti-
body were added to the wells. After incubation for 3.5h
at 37 C in a 5% CO2 incubator, the cells were stained with
propidium iodide (PI). Data were acquired using the
Becton Dickinson LSR II and analysed with FlowJo soft-
ware 7.2.2.
In vitro Fc-dependent cellular cytotoxicity
Primary B cells (targets) and NK cells (effectors) were iso-
lated from the same donor. B cells were labelled with
0.3mM carboxy-fluorescein diacetate, succinimidyl ester
(CFSE) for 15min at 37 C and incubated with varying con-
centrations of the SMIP proteins or rituximab for 30min at
37 C. NK cells were added at a 1:4 target: effector ratio
to the wells. The cells were incubated for 4h at 37 C and
then stained with 7-AAD. Data were acquired using
Becton Dickinson LSR II and analysed with FlowJo soft-
ware 7.2.2.
Direct killing assay
Primary human B cells were treated with varying concen-
trations (0.01500nM) of 2LM20-4, 2LM20-4 P331S, ritux-
imab or control antibody for 22 and 72h at 37 Ci na5 %
CO2 incubator. The cells were washed and stained with
annexin V-allophycocyanin (APC) and PI, then washed
again and analysed by flow cytometry on the BD LSR II.
The percentage of live cells was calculated as cells that
were negative for both annexin V and PI.
In vivo pharmacodynamic and pharmacokinetic study
Forty female naı ¨ve cynomolgus monkeys (Macaca fasci-
cularis) were assigned to the study. The study was per-
formed at a contract laboratory in accordance with the
institution’s Institutional Animal Care and Use Committee
(IACUC) guidelines and was approved by Pfizer’s
Institutional Animal Care and Use Committee. The animals
were acclimated for 14 days (A114). Groups (four mon-
keys/group) were administered single i.v. dosages of 1 or
10mg/kg of anti-CD20 proteins according to Table 1.
Flow cytometric immunophenotyping was conducted
on peripheral blood, lymph nodes and bone marrow sam-
ples using antibodies to CD3, CD19, CD20 and CD45
(CD3-FITC, CD19-APC, CD45-PE and CD20-APC; BD
Pharmingen, San Diego, CA, USA).
TABLE 1 In vivo experimental protocol
Group Test article
Dose
(mg/kg) Surgery
Number
of animals
1 Vehicle 0 No 4
2 Rituximab 1 No 4
3
a Rituximab 10 Yes 4
4
b Rituximab 10 No 4
5 2LM20-4 1 No 4
6
a 2LM20-4 10 Yes 4
7
b 2LM20-4 10 No 4
8 2LM20-4 P331S 1 No 4
9
a 2LM20-4 P331S 10 Yes 4
10
b 2LM20-4 P331S 10 No 4
aAnimals in Groups 3, 6 and 9 underwent surgery (bone
marrow aspirates and lymph node biopsies).
bAnimals in
Groups 4, 7 and 10 did not have bone marrow aspirates and
lymph node biopsies and were included for the evaluation of
the impact of surgery on peripheral blood results.
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Log transformation was applied to the data on relative per-
cent of CD19
+ lymphocytes before a linear mixed model
analysis was performed. In the linear mixed model, the
fixed effects included treatment group, day and their inter-
action. The correlation between repeated measurements
on the same animals was modelled with a first-order auto-
regressive matrix. Contrasts in the framework of the linear
mixed model were used for all comparisons.
Results
2LM20-4 and 2LM20-4 P331S have comparable
binding to primary B cells
2LM20-4 was constructed based on the mAb 2H7. The
modular design of SMIP molecules allows the combin-
ation of various antigen-binding domains with Fc domains
of human antibodies through a flexible hinge sequence
(Fig. 1A and B). 2LM20-4 and 2LM20-4 P331S had iden-
tical binding in all our flow cytometry binding assays
(Fig. 1C). At the concentrations tested, rituximab reprodu-
cibly demonstrated higher saturation binding to human
primary B cells compared with 2LM20-4 and 2LM20-4
P331S, as indicated by a higher mean fluorescence inten-
sity (MFI). Confocal microscopy was also used to visualize
the binding of biotinylated reagents to CD20 on primary
B cells. Both rituximab and 2LM20-4 showed a diffuse
staining pattern of binding over the cell surface, but cells
stained with rituximab were significantly brighter com-
pared with cells stained with 2LM20-4 or control antibody
(Fig. 1D). These results suggest that 2LM20-4 may recog-
nize only a proportion of CD20 molecules as compared
with rituximab.
2LM20-4 has lower Kd and recruits fewer CD20
molecules than rituximab into lipid rafts
In direct binding studies with primary B cells using
125I-labelled reagents, 2LM20-4 showed a Kd of 0.95nM
(Fig. 2A) and rituximab a Kd of 0.15nM (Fig. 2B). Also,
Scatchard plots for rituximab were linear and predicted
27000receptors/cell, whereas Scatchard plots for
2LM20-4 were curved and fitted non-linear regression for
two-site binding (Fig. 2C). The lower level of binding by
2LM20-4 suggests that while it binds two sites, it does
not bind either one to saturation. To test the degree of as-
sociation of
125I-2LM20-4 and
125I-rituximab with CD20
molecules in lipid rafts, we followed the Triton X-100 solu-
bilization protocol, previously used for the characterization
ofdetergent-insolublemicrodomainsuponbindingofritux-
imab to CD20 on B cells. The experiments were repeated
several times using Ramos B cells and they reproducibly
showed significantly higher per cent of Triton X-100 insol-
uble fraction for rituximab compared with 2LM20-4
(Fig. 2D). These results indicate that there are significant
differences between the binding properties of 2LM20-4
and rituximab to CD20.
2LM20-4 shows partial displacement of rituximab in
direct binding assays
In competitive direct binding assays, different amounts of
cold competitor, up to a 20-fold excess, resulted in partial
displacement of
125I-rituximab on primary B cells (Fig. 3A).
In flow cytometry direct binding assays, primary B cells
were incubated for 1h and overnight (Fig. 3B) with labelled
anti-CD20 molecules and a 100-fold excess of unlabelled
anti-CD20 molecules. Labelled 2LM20-4 was completely
competed by excess unlabelled rituximab; however,
labelled rituximab was only partially competed by excess
unlabelled 2LM20-4, with a loss of diffuse cell surface
staining by rituximab but maintenance of staining at cell:
cell contacts. As expected, both excess cold rituximab
and 2LM20-4 completely competed labelled rituximab
and 2LM20-4, respectively. Similar findings were observed
with confocal microscopy (Fig. 3C). A fluorescent signal
was retained when staining with labelled rituximab and
excess unlabelled 2LM20-4, whereas staining by labelled
2LM20-4 was completely abolished when excess un-
labelled rituximab was present. These competition experi-
ments suggest that, while rituximab and 2LM20-4 share
an epitope on CD20, 2LM20-4 is able to compete with
rituximab binding to CD20 only when rituximab is bound
to CD20 in soluble areas of the plasma membrane.
Mutation P331S in the CH2 domain eliminates the
in vitro CDC activity of 2LM20-4
The P331 residue has been previously identified as
required for C1q binding to the Fc region of an IgG1 mol-
ecule [29]. In CDC assays performed using B cells from
multiple healthy donors, 2LM20-4 demonstrated the high-
est CDC activity with a maximum of 80% of cell lysis,
whereas 2LM20-4 P331S had no CDC activity and was
similar to control antibody (Fig. 4A). Interestingly, rituximab
showed 50% cell lysis and, therefore, lower CDC activity
compared with 2LM20-4, despite the higher affinity and
slower off rate of binding to CD20 on primary B cells
(Fig. 4A).
2LM20-4 and 2LM20-4 P331S have comparable
Fc-mediated cellular toxicity
2LM20-4, 2LM20-4 P331S and rituximab each demon-
strated Fc-mediated cellular toxicity in a dose-dependent
manner, as shown in Fig. 4B. Overall, 2LM20-4 had a
trend of higher Fc-mediated cytotoxicity compared with
rituximab, particularly at high concentrations; however,
this finding never achieved statistical significance. These
results indicate that 2LM20-4 induces potent Fc-mediated
cytotoxicity and that the P331S mutation does not affect
functional interactions of 2LM20-4 to FcgR receptors on
human NK cells.
2LM20-4 and 2LM20-4 P331S do not induce direct
killing of normal human B cells
It has been demonstrated that rituximab arrests cell
growth and also causes apoptosis in some CD20
+ B-cell
lines if cross-linked with a secondary anti-immunoglobulin
antibody [30]. In a recent report, the type II anti-CD20
1036 www.rheumatology.oxfordjournals.org
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mode of cell death in human B-cell lymphoma lines
without secondary cross-linking [31]. Here, we performed
PCD assays without secondary cross-linking. As shown in
Fig. 4C, no specific killing of primary human B cells was
observed at 22 h with varying concentrations of 2LM20-4,
2LM20-4 P331S or rituximab. Similarly, no specific killing
of primary human B cells was observed at 72h with
varying concentrations of 2LM20-4, 2LM20-4 P331S or
rituximab (data not shown).
FIG.12LM20-4 has a modular design and has lower saturation binding compared with rituximab. (A) Illustration of the
structural domains of an antibody; dotted squares indicate the domains used for generation of the SMIP. (B) Structure
of 2LM20-4. (C) Binding of 2LM20-4, 2LM20-4 P331S and rituximab to CD20 on primary human B cells. Similar results
were obtained using several different donors; data from one donor are shown. (D) Confocal images showing binding
of biotinylated 2LM290-4 or rituximab to primary B cells. Blue stain (TO-PRO 3) shows nuclear binding, red stain shows
binding to CD20.
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Characteristics of B-cell targeted SMIP 2LM20-4FIG.22LM20-4 has lower Kd and recruits fewer CD20 molecules than rituximab into lipid rafts. Kds were determined
using
125Iodine-labelled 2LM20-4 or rituximab and primary B cells. Each Kd determination was repeated three times with
the same donor. GraphPad Prism software was used for curve fitting. The total, 2LM20-4-specific and non-specific
(A), or rituximab-specific and non-specific (B) binding is shown. (C) Scatchard plots for 2LM20-4 (curved) and rituximab
(linear). (D) Ramos B cells were incubated with iodinated anti-CD20 molecules for 060min. Cells pellets were lysed
with 0.5% Triton X-100. Soluble and insoluble lysate fractions were counted on a gamma counter followed by the
determination of the distribution of radio labelled proteins in the soluble vs insoluble fractions.
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Cheryl Nickerson-Nutter et al.FIG.32LM20-4 shows partial displacement of rituximab in direct binding assays. (A) Excess of unlabelled 2LM20-4 only
partially displaced
125I-rituximab binding to CD20 on primary B cells. (B) B cells were treated for 1 and 24h with
biotinylated anti-CD20 molecules. The competitor was added first, and the biotinylated anti-CD20 added last. The cells
were stained with Alexa Fluor 568-SA and aliquots were used for staining with 7AAD and CD19APC and FACS analysis.
(C) The rest of the cells were spun onto microscope slides, nuclei stained with TO-PRO 3 and cells visualized by confocal
microscopy. The 1-h time point is shown.
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CD19
+ B-cell depletion activity compared with
rituximab
CD19
+ B-cell depletion and recovery in the peripheral
blood of the cynomolgus monkeys that received
10mg/kg of 2LM20-4, 2LM20-4 P331S or rituximab are
shown in Fig. 5A. All three proteins had very potent and
comparable activity during the first 3 weeks after dosing;
however, significant B-cell recovery was observed earlier
in the rituximab-treated group. All the groups had signifi-
cant CD19
+ B-cell repletion by 6 months. The effect of a
single i.v. 10mg/kg dose of anti-CD20 molecules on the
percentage of CD19
+ B cells in the bone marrow is
shown in Fig. 5B. All the three proteins significantly
decreased the percentage of CD19
+ B cells by Day 8.
The percentage of CD19
+ B cells returned to baseline
levels in the rituximab-treated monkeys by Day 22. In con-
trast, the percentage remained significantly decreased in
the 2LM20-4 and 2LM20-4 P331S groups on Day 22. By
the end of the study (D179), the number of CD19
+ B cells
had returned to baseline levels in all of the groups. These
results show that 2LM20-4 has very potent peripheral
blood B-cell depletion activity, which is more sustained
compared with 2LM20-4 P331S and rituximab, and that
both SMIP proteins have more sustained depletion in the
bone marrow compared with rituximab.
2LM20-4 demonstrates more potent and sustained
lymph node CD19
+ B-cell depletion activity compared
with 2LM20-4 P331S and rituximab
The effect of a single i.v. 10mg/kg dose of 2LM20-4,
2LM20-4 P331S or rituximab on the percentage of
CD19
+ B cells in the lymph nodes is shown in Fig. 6.
There was a significant decrease in the number of
CD19
+ B cells in the lymph nodes of all groups by
Day 8. This depletion was more profound in the rituximab
and 2LM20-4-treated groups with >75% depletion of the
CD19
+ cells compared with 50% in the 2LM20-4 P331S
group. By Day 29, the number of CD19
+ B cells had
significantly increased in the rituximab group, but not in
the 2LM20-4 and 2LM20-4 P331S groups. Notably, the
2LM20-4 group had even fewer CD19
+ B cells than on
Day 8. By the end of the study, there was a full recovery
in the percentage of CD19
+ cells in all groups. No changes
were observed in the histopathology examination in each
group by the end of the study (data not shown). Also, no
differences were noted in CD3-, CD20- or CD68-positive
cells in inguinal lymph nodes in any of the animals in
Groups 3, 6 and 9 and in the vehicle group (data not
shown). These results demonstrate that 2LM20-4 has
significantly more potent activity in the lymph nodes
compared with 2LM20-4 P331S and rituximab, indicating
that, in addition to other mechanisms, CDC effector func-
tion has a major role in the elimination of lymph node
B cells in cynomolgus monkeys.
Discussion
Work on the mechanisms of B-cell killing by anti-CD20
mAbs has categorized anti-CD20 mAbs as type I and
the rare type II [14, 31]. Although this classification clearly
encompasses a broad spectrum of the in vitro properties
that have been attributed to anti-CD20 mAbs in previous
reports, here we present evidence that 2LM20-4 cannot
be classified either as a type I or a type II anti-CD20
FIG.42LM20-4 induces potent CDC and Fc-mediated
cellular toxicity, but no PCD. (A) In vitro CDC of 2LM20-4,
2LM20-4 P331S, rituximab or control IgG1 on primary
human B cells. (B) In vitro Fc-mediated cellular toxicity
by 2LM20-4, 2LM20-4 P331S, rituximab or control IgG1
against primary human B cells in the presence of
autologous NK cells (effectors). (C) PCD induction by
2LM20-4, 2LM20-4 P331S, rituximab or control IgG1 was
assessed on primary human B cells after 22h using flow
cytometry. Similar results were obtained using different
healthy donors; for each effector function results from one
donor are shown.
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Cheryl Nickerson-Nutter et al.molecule. 2LM20-4 binds to significantly fewer CD20 mol-
ecules on primary B cells compared with rituximab, as
shown by flow cytometry, direct binding and confocal
assays (Fig. 1C and D). These data would suggest that
2LM20-4 primarily binds to CD20 molecules in soluble
regions of the plasma membrane, whereas rituximab is
able to interact with, or drive CD20 into insoluble regions.
Also, the competition experiments suggest that 2LM20-4
is able to compete rituximab bound to CD20 preferentially
in soluble regions of the plasma membrane. It is possible
that the higher binding affinity (Fig. 2A and B) of rituximab
results in increased binding of CD20 in insoluble areas as
compared with 2LM20-4. Another possible interpretation
for the lower saturation binding of 2LM20-4 in Fig. 1C and
D is that, due to the intrinsic nature of the SMIP scaffold, it
can simultaneously bind to two molecules of CD20, and,
therefore, it only necessitates half the amount of protein
required to occupy the available CD20 molecules com-
pared with rituximab. However, the competition binding
assays do not support this hypothesis, as a 100-fold
molar excess of 2LM20-4 only partially displaces rituxi-
mab (Fig. 3AC). Overall, these finding suggest that
2LM20-4 and rituximab may recognize differentially loca-
lized CD20 molecules, which results in the different stain-
ing levels and patterns observed in cells. This is also
supported by our Triton X-100 findings, which show that
2LM20-4 recruits significantly fewer CD20 molecules into
lipid rafts compared with rituximab (Fig. 2C). Recently, it
FIG.5B-cell depletion activity of anti-CD20 molecules in the peripheral blood and bone marrow of cynomolgus
monkeys. (A) Absolute numbers of CD19
+ B cells monitored in the peripheral blood with flow cytometry. *Significantly
different from 2LM20-4 P331S and 2LM20-4; **significantly different from 2LM20-4 only; ***2LM20-4 significantly different
from 2LM20-4 P331S and from rituximab;
#all three groups are different from each other. (B) Kinetics of bone marrow
CD19
+ B-cell depletion and recovery. *Significant from baseline acclimation values at P<0.05 by a linear mixed model
analysis. All data are presented as the mean (S.D.) percentage of CD19
+ lymphocytes relative to acclimation Day 7 (A7).
0
20
40
60
80
100
120
140
A7
D2
D3
D4
D8
D15
D25
D32
D39
D46
D53
D60
D67
D74
D102
D130
D158
D178
C
D
1
9
+
 
l
y
m
p
h
o
c
y
t
e
s
 
r
e
l
a
t
i
v
e
 
t
o
 
D
a
y
 
A
7
,
 
%
Vehicle
10 mg/kg rituximab
10 mg/kg 2LM20-4
10 mg/kg 2LM20-4 P331S
*
*
**
**
***
##
**
**
***
0
50
100
150
200
*
*
2LM20-4 P331S
2LM20-4
*
*
*
Day 8D a y 22 Day 179
Rituximab
C
D
1
9
+
 
b
o
n
e
 
m
a
r
r
o
w
 
c
e
l
l
s
 
r
e
l
a
t
i
v
e
 
t
o
 
D
a
y
 
A
7
,
 
%
A
B
Days 
Time (days) 
www.rheumatology.oxfordjournals.org 1041
Characteristics of B-cell targeted SMIP 2LM20-4has been shown that homotypic adhesion followed by
lysosome-mediated cell death are the mechanisms under-
lying B-cell death induced by type II anti-CD20 mAbs [31].
2LM20-4 has none of these type II characteristics: it has
no ability to induce homotypic adhesion of either primary
B cells or B-cell lymphoma lines, as assessed by light
microscopy (data not shown), and does not initiate PCD
in either primary B cells (Fig. 4C) or B-cell lymphoma lines
(data not shown).
It is noteworthy that 2LM20-4 has increased CDC as
compared with rituximab despite its higher off-rate (data
not shown) and its reduced ability to recruit CD20 into
Triton-insoluble microdomains. Previous reports have
shown that the activation of the large hexameric glycopro-
tein C1q requires fixation of its globular heads at an angle
that favours autoactivation of the tetrameric C1rC1s com-
ponents [32]. Thus, the CDC activity of 2LM20-4, as of
most anti-CD20 mAbs, may be attributable to the small
size of the extracellular domain of CD20 and can be ex-
plained by critical dependence on the distance between
the plasma membrane and the constant regions of the
sensitizing antibody [33, 34]. In this regard, the SMIP
structure of 2LM20-4 offers a potential explanation for
its more potent CDC compared with rituximab, as it may
deliver C1q closer to the cell membrane. Teeling et al. [35]
had initially proposed that the off-rate of the mAb controls
the amount of C1q that binds on the cell surface. 2LM20-4
has fast off-rate (data not shown), and this may facilitate
its re-binding to B cells and activation of complement,
leading ultimately to higher CDC activity. In support of
this is the longer half-life (t½) of 2LM20-4 compared with
rituximab [7.8±1.5 and 5.4±2.0 days in the 10mg/kg
dose groups, respectively; data not shown]. Teeling
et al. [35] also determined that the locality at which com-
plement is activated, and the epitope on CD20 also could
play a role [16]. 2LM20-4 originates from the 2H7 mouse
antibody, which was epitope mapped and was shown to
recognize a similar epitope to rituximab [16]. Despite this
overlapping in binding epitopes, our results of cell-surface
binding and competition experiments suggest that
2LM20-4 recognizes only a proportion of CD20 molecules
on the B cells. Overall, we conclude that the distinct bind-
ing properties of 2LM20-4 that can be attributed, at least
partially, to its modular SMIP configuration, may favour
capturing of C1q via multiple globular heads, thus holding
it long enough in a conformation that is required for auto-
activation and induction of potent CDC activity. The ques-
tion remains whether it is the binding domain with its
higher off-rate or the SMIP structure that more efficiently
mediates complement-induced killing of cells.
In the in vivo cynomolgus monkey B-cell depletion
model, both 2LM20-4 and 2LM20-4 P331S have favour-
able pharmacokinetic profiles (data not shown) and equally
potent B-cell depletion activity in the peripheral blood and
bone marrow, which is more sustained than that observed
withrituximab.Mostimportantly,2LM20-4hassignificantly
higher activity in the lymph nodes compared with 2LM20-4
P331S, and significantly prolonged activity compared with
rituximab, indicating that CDC activity may be required
for more effective B-cell depletion in some tissues of cyno-
molgus monkeys. These findings are in agreement with the
concept that the mechanism of B-cell depletion may vary
with different compartments and indicates that B cells
within lymphoid tissues that have reduced circulatory cap-
acity might exhibit a greater dependence on complement-
rather than Fc receptor-mediated mechanisms for
FIG.6B-cell depletion activity of anti-CD20 molecules in lymph nodes of cynomolgus monkeys. Kinetics of lymph node
CD19
+ B-cell depletion and recovery were analysed with flow cytometry at the indicated time points. Data are presented
as the mean (S.D.) percentage of CD19
+ lymphocytes relative to acclimation Day 7 (A7). *Significant from baseline
acclimation values at P<0.05 by a linear mixed model analysis; **significantly different between indicated groups
at<0.05 by a linear mixed model analysis.
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Cheryl Nickerson-Nutter et al.depletion. These results point to two major conclusions:
first, the in vitro binding properties of an anti-CD20 mol-
ecule are not predictive of its in vivo B-cell depletion po-
tency: 2LM20-4 binds to only a fraction of CD20 molecules
as compared with rituximab; however, 2LM20-4 appears
to have more potent and sustained B-cell depletion activity
in the cynomolgus monkey study. Secondly, high CDC ac-
tivity is required for more potent and sustained B-cell de-
pletion in lymphoid tissues, as 2LM20-4 has significantly
more potent and sustained activity compared not only with
2LM20-4 P331S, but also with rituximab in cynomolgus
monkeys.
In conclusion, we have shown that SMIP 2LM20-4,
which has a distinct in vitro binding profile, has profound
andsustainedB-celldepletionactivityincynomolgusmon-
keys. These results provide fresh insight into how anti-
CD20 molecules may potentiate their in vitro and in vivo
B-cell depletion activity and indicate that 2LM20-4 repre-
sents a very promising B-cell-depleting drug candidate
with unique properties that support clinical evaluation in
patients with B-cell-dependent autoimmune disorders.
Rheumatology key messages
. In vitro binding to CD20 is not predictive of in vivo
B-cell depletion potency.
. CDC activity is required for potent B-cell depletion
in lymph nodes of cynomolgus monkeys.
. SMIP 2LM20-4 represents a promising B-cell-
depleting drug candidate for treatment of auto-
immune diseases.
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